GlassScriptPhysician profile
Lisa Sande
NPI 1396270625
$2,410.56
in general payments reported to CMS, 2019-2025
31 companies · $678 in 2025
The $678 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $319 · 2023: $618 · 2024: $669 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.00 | 2024-2025 | |
| Immedica Pharma US, INC. | $312.31 | 2022-2024 | |
| Ucb, INC. | $307.95 | 2022-2024 | Fintepla, Briviact, Rystiggo |
| Jazz Pharmaceuticals INC. | $164.46 | 2022-2024 | |
| Lundbeck LLC | $141.46 | 2024 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $108.32 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sk Life Science, INC. | $84.06 | 2021-2023 | |
| Neurelis, INC. | $74.47 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.32 | 2025 | Caplyta |
| Tg Therapeutics, INC. | $72.38 | 2025 | |
| Acadia Pharmaceuticals INC | $64.61 | 2023-2024 | Daybue |
| Impel Pharmaceuticals INC. | $43.66 | 2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $36.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.68 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $30.17 | 2023-2024 | Fycompa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29.93 | 2022 | |
| Argenx US, INC. | $29.76 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $28.39 | 2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $24.72 | 2023 | Acthar |
| Amneal Pharmaceuticals LLC | $24.45 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $24.08 | 2023 | Jornay Pm |
| Alkermes, INC. | $21.97 | 2025 | Vivitrol |
| Sumitomo Pharma America, INC. | $19.38 | 2023 | Aptiom |
| Vanda Pharmaceuticals INC. | $18.52 | 2024 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $18.38 | 2024 | Rexulti |
| Biomarin Pharmaceutical INC. | $17.03 | 2024 | Brineura |
| Azurity Pharmaceuticals, INC. | $16.95 | 2024 | Zonisade |
| Lilly USA, LLC | $16.75 | 2024 | Amyvid |
| Zogenix INC. | $15.93 | 2021 | |
| Cranial Technologies, INC | $12.90 | 2022 | |
| Livanova USA, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Sande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.